Remicade biosimilar: J&J’s ‘fear and loathing’ subdued as Pfizer slugs it out
Fears of Remicade competition have not manifested in significant growth declines for Johnson & Johnson, but Pfizer says US payers and physicians are slowly getting comfortable with biosimilars.